Seiji Fukumoto
Overview
Explore the profile of Seiji Fukumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
239
Citations
6811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ito N, Kang H, Michigami T, Namba N, Kubota T, Shintani A, et al.
Calcif Tissue Int
. 2025 Mar;
116(1):50.
PMID: 40074938
In patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Asia, the current prevalence of hyperparathyroidism and its association with renal dysfunction have not been determined. We used patient data retrospectively collected...
2.
Ali D, Carpenter T, Imel E, Ward L, Appelman-Dijkstra N, Chaussain C, et al.
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39960858
Background: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have...
3.
Ali D, Mirza R, Hussein S, Alsarraf F, Alexander R, Abu Alrob H, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39787354
Objective: To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations. Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up...
4.
Ali D, Mirza R, Alsarraf F, Hussein S, Abu Alrob H, Appelman-Dijkstra N, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39715351
Objective: To examine the highest certainty evidence addressing the management of X-linked hypophosphatemia (XLH) in adults to inform treatment recommendations. Methods: We searched Embase, MEDLINE, Web of Science, and Cochrane...
5.
Namba N, Ito N, Michigami T, Kang H, Kubota T, Miyazaki O, et al.
JBMR Plus
. 2024 Oct;
8(11):ziae118.
PMID: 39399158
The SUNFLOWER study was initiated in Japan and South Korea to clarify the course of X-linked hypophosphatemic rickets/osteomalacia (XLH); delineate its physical, mental, and financial burdens; and collect information on...
6.
Michigami T, Kang H, Namba N, Ito N, Kubota T, Shintani A, et al.
JBMR Plus
. 2024 Jul;
8(8):ziae079.
PMID: 39015507
X-linked hypophosphatemia (XLH) is a genetic disease that results in excessive FGF23, chronic hypophosphatemia, and musculoskeletal abnormalities, with affected patients experiencing symptoms such as bone pain, bone deformity, fracture, and...
7.
Hidaka N, Inoue K, Kato H, Hoshino Y, Koga M, Kinoshita Y, et al.
JACC Adv
. 2024 Jun;
3(1):100747.
PMID: 38939808
Background: In patients with chronic kidney disease (CKD), fibroblast growth factor (FGF)-23 is suspected to cause death or cardiovascular disease by inducing left ventricular hypertrophy (LVH). Objectives: This study aims...
8.
Takashi Y, Kawanami D, Fukumoto S
Curr Opin Endocrinol Diabetes Obes
. 2024 Apr;
31(4):170-175.
PMID: 38687287
Purpose Of Review: Fibroblast growth factor 23 (FGF23) is a hormone to reduce blood phosphate concentration. Excessive actions of FGF23 induce FGF23-related hypophosphatemic disorders, such as X-linked hypophosphatemic rickets (XLH)...
9.
Taguchi T, Matsushima H, Kodama S, Okubo N, Ito T, Ludwikowska M, et al.
Expert Opin Pharmacother
. 2024 Apr;
25(3):325-334.
PMID: 38588537
Background: Hormone therapy with aromatase inhibitors (AIs) for estrogen receptor-dependent breast cancer may expose patients to an increased osteoporosis risk. This study was performed to estimate fracture risk in women...
10.
Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, et al.
J Bone Miner Metab
. 2024 Mar;
42(2):143-154.
PMID: 38538869
Introduction: Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50%...